Novozymes' bioenergy unit exceeds consensus amid wide H1 setback
Novozymes' bioenergy unit was the company's only division to perform better than expected. Altogether, the group had to swallow a negative organic growth of 3 percent for the first half of 2019.
BY VICTOR EMIL KRISTENSEN
Danish enzyme producer Novozymes published an expectedly disappointing biannual financial statement Thursday morning and thereby continues into a 2019 that Chief Executive Peder Holk Nielsen would likely prefer to forget.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novozymes has underestimated fluctuating bioenergy industry
For subscribers
BP launches new biofuel joint venture
For subscribers
Novozymes downgrades following failing sales
For subscribers
